447 related articles for article (PubMed ID: 19268732)
1. Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).
Taglieri N; Saia F; Guiducci V; Tondi S; Conrotto F; Marrozzini C; Rocchi G; Biagini E; Reggiani ML; Giacometti P; Piovaccari G; Manari A; Marzocchi A;
Am J Cardiol; 2009 Mar; 103(6):785-90. PubMed ID: 19268732
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial.
Marzocchi A; Manari A; Piovaccari G; Marrozzini C; Marra S; Magnavacchi P; Sangiorgio P; Marinucci L; Taglieri N; Gordini G; Binetti N; Guiducci V; Franco N; Reggiani ML; Saia F;
Eur Heart J; 2008 Dec; 29(24):2972-80. PubMed ID: 18940887
[TBL] [Abstract][Full Text] [Related]
3. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.
Bellandi F; Maioli M; Gallopin M; Toso A; Dabizzi RP
Catheter Cardiovasc Interv; 2004 Jun; 62(2):186-92. PubMed ID: 15170708
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
5. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
[TBL] [Abstract][Full Text] [Related]
6. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
Hassan AK; Liem SS; van der Kley F; Bergheanu SC; Wolterbeek R; Bosch J; Bootsma M; Zeppenfeld K; van der Laarse A; Atsma DE; Jukema JW; Schalij MJ
Catheter Cardiovasc Interv; 2009 Aug; 74(2):335-43. PubMed ID: 19642182
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
[TBL] [Abstract][Full Text] [Related]
8. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
Valgimigli M; Percoco G; Malagutti P; Campo G; Ferrari F; Barbieri D; Cicchitelli G; McFadden EP; Merlini F; Ansani L; Guardigli G; Bettini A; Parrinello G; Boersma E; Ferrari R;
JAMA; 2005 May; 293(17):2109-17. PubMed ID: 15870414
[TBL] [Abstract][Full Text] [Related]
9. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial).
Maioli M; Bellandi F; Leoncini M; Toso A; Dabizzi RP
J Am Coll Cardiol; 2007 Apr; 49(14):1517-24. PubMed ID: 17418289
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A
J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130
[TBL] [Abstract][Full Text] [Related]
11. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
Gunasekara AP; Walters DL; Aroney CN
Int J Cardiol; 2006 Apr; 109(1):16-20. PubMed ID: 16014315
[TBL] [Abstract][Full Text] [Related]
12. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up.
Mukherjee D; Topol EJ; Bertrand ME; Kristensen SD; Herrmann HC; Neumann FJ; Yakubov SJ; Bassand JP; McClure RR; Stone GW; Ardissino D; Moliterno DJ;
Eur Heart J; 2005 Dec; 26(23):2524-8. PubMed ID: 16107485
[TBL] [Abstract][Full Text] [Related]
13. ST-segment analysis to predict infarct size and functional outcome in acute myocardial infarction treated with primary coronary intervention and adjunctive abciximab therapy.
Sciagrà R; Parodi G; Migliorini A; Valenti R; Antoniucci D; Sotgia B; Pupi A
Am J Cardiol; 2006 Jan; 97(1):48-54. PubMed ID: 16377283
[TBL] [Abstract][Full Text] [Related]
14. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ; Mehran R; Hooper WC; Moses JW; Weisz G; Collins MB; Lansky AJ; Kreps EM; Leon MB; Stone GW; Dangas G
J Invasive Cardiol; 2010 Jan; 22(1):2-6. PubMed ID: 20048389
[TBL] [Abstract][Full Text] [Related]
15. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
[TBL] [Abstract][Full Text] [Related]
16. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Valgimigli M; Campo G; Malagutti P; Anselmi M; Bolognese L; Ribichini F; Boccuzzi G; de Cesare N; Rodriguez AE; Russo F; Moreno R; Biondi-Zoccai G; Penzo C; Díaz Fernández JF; Parrinello G; Ferrari R
JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629
[TBL] [Abstract][Full Text] [Related]
17. Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery.
Tödt T; Sederholm-Lawesson S; Stenestrand U; Alfredsson J; Janzon M; Swahn E
Acute Card Care; 2010 Mar; 12(1):10-7. PubMed ID: 20201657
[TBL] [Abstract][Full Text] [Related]
18. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.
Danzi GB; Sesana M; Capuano C; Mauri L; Berra Centurini P; Baglini R
Am J Cardiol; 2004 Jul; 94(1):35-9. PubMed ID: 15219505
[TBL] [Abstract][Full Text] [Related]
19. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
[TBL] [Abstract][Full Text] [Related]
20. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis.
De Luca G; Ucci G; Cassetti E; Marino P
J Am Coll Cardiol; 2009 May; 53(18):1668-73. PubMed ID: 19406342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
